Both TSAs and TAAs have been evaluated for suitability towards vaccine development in breast cancer in preclinical and early-clinical studies in order to elicit a CD8+ T-cell (cytotoxic T lymphocyte, or CTL) and Natural Killer Cell (NKT) response. This evidence concerns the gene CD8A and breast carcinoma.